

Aldevron Now Offering Its pALD-HELP Plasmid for Viral Vector Production in GMP-Source® Quality Level

AAV Product Provides High-Quality, In-Stock Option for Companies Needing Option to Enter Clinical Space

FARGO, NORTH DAKOTA, UNITED STATES, December 7, 2021 /EINPresswire.com/ -- Aldevron is

“

Offering pALD-HELP in our GMP-Source quality level is another way we can support our clients in their efforts to get potential therapies to their patients sooner.”

Michelle Berg

now offering its pALD-HELP, an off-the-shelf product supporting AAV viral vector manufacturing, in its proprietary GMP-Source® (GMP-S) quality level. The plasmid is royalty-free for all applications in support of pre-clinical activities through clinical development.

The addition of this widely used plasmid expands Aldevron’s suite of ready-to-use and royalty-free constructs in support of making AAV via triple transfection, including its rep/cap plasmids 2, 5 and 6. The pALD-AAV6 plasmid is

also available at the GMP-Source quality level.

“We launched this Ad helper plasmid in Research Grade as an inventory product earlier this fall and it was very well received,” said Michelle Berg, President, GMP Nucleic Acids for Aldevron.

“Offering pALD-HELP in our GMP-Source quality level is another way we can support our clients in their efforts to get potential therapies to their patients sooner. Aldevron continuously looks for ways to improve our service to clients and expanding our portfolio of standardized products across quality levels ensures they have the quality products they need, when they need them.”

Aldevron has more than 23 years of experience manufacturing high-quality custom products that are used by companies around the world, along with a catalog of products that provide a consistent, reliable option to help clients meet deadlines. In addition to the AAV construct suite, Aldevron’s inventory product lines also include lentivirus plasmids, IVT enzymes, and a variety of CRISPR nucleases.

About Aldevron

Aldevron is a premier manufacturing partner in the global genetic medicine field. Founded in 1998 by Michael Chambers and John Ballantyne, the company provides critical nucleic acids and

proteins used to make gene and cell therapies, DNA and RNA vaccines, and gene editing technologies. Aldevron's 700+ employees support thousands of scientists who are developing revolutionary treatments for millions of people. For more information, visit aldevron.com

Ellen Shafer

Aldevron

+1 701-551-8704

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/557817408>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.